Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Hill, R.M., Kuijper, S., Lindsey, J.C., Petrie, K., Schwalbe, E.C., Barker, K., Boult, J.K., Williamson, D., Ahmad, Z., Hallsworth, A., et al. (2015). Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer cell, Vol.27 (1), pp. 72-84.  show abstract

DuBois, S.G., Chesler, L., Groshen, S., Hawkins, R., Goodarzian, F., Shimada, H., Yanik, G., Tagen, M., Stewart, C., Mosse, Y.P., et al. (2012). Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin cancer res, Vol.18 (9), pp. 2679-2686.  show abstract

Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W.R., Hallsworth, A., et al. (2012). The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer cell, Vol.22 (1), pp. 117-130.  show abstract

Swartling, F.J., Savov, V., Persson, A.I., Chen, J., Hackett, C.S., Northcott, P.A., Grimmer, M.R., Lau, J., Chesler, L., Perry, A., et al. (2012). Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer cell, Vol.21 (5), pp. 601-613.  show abstract

Moreno, L., Chesler, L., Hargrave, D., Eccles, S.A. & Pearson, A.D. (2011). Preclinical drug development for childhood cancer. Expert opin drug dis, Vol.6 (1), pp. 49-64.  show abstract

Chesler, L. & Weiss, W.A. (2011). Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Semin cancer biol, Vol.21 (4), pp. 245-255.  show abstract

Faisal, A., Vaughan, L., Bavetsias, V., Sun, C., Atrash, B., Avery, S., Jamin, Y., Robinson, S.P., Workman, P., Blagg, J., et al. (2011). The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol cancer ther, Vol.10 (11), pp. 2115-2123.  show abstract

Swartling, F.J., Grimmer, M.R., Hackett, C.S., Northcott, P.A., Fan, Q.-., Goldenberg, D.D., Lau, J., Masic, S., Nguyen, K., Yakovenko, S., et al. (2010). Pleiotropic role for MYCN in medulloblastoma. Genes dev, Vol.24 (10), pp. 1059-1072.  show abstract

Chesler, L., Goldenberg, D., Collins, R., Grimmer, M., Kim, G.E., Tihan, T., Nguyen, K., Yakovenko, S., Matthay, K.K. & Weiss, W.A., et al. (2008). Chemotherapy-Induced Apoptosis in a Transgenic Model of Neuroblastoma Proceeds Through p53 Induction. Neoplasia, Vol.10 (11), pp. 1268-U93.  show abstract

Chesler, L., Schlieve, C., Goldenberg, D.D., Kenney, A., Kim, G., McMillan, A., Matthay, K.K., Rowitch, D. & Weiss, W.A. (2006). Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer res, Vol.66 (16), pp. 8139-8146.  show abstract